335 related articles for article (PubMed ID: 17148739)
21. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
22. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Tomlinson JW; Stewart PM
Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
[TBL] [Abstract][Full Text] [Related]
24. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.
Rask E; Walker BR; Söderberg S; Livingstone DE; Eliasson M; Johnson O; Andrew R; Olsson T
J Clin Endocrinol Metab; 2002 Jul; 87(7):3330-6. PubMed ID: 12107245
[TBL] [Abstract][Full Text] [Related]
25. [Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome].
Góth M; Hubina E; Korbonits M
Orv Hetil; 2005 Jan; 146(2):51-5. PubMed ID: 15724952
[TBL] [Abstract][Full Text] [Related]
26. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
27. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
28. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.
Wake DJ; Rask E; Livingstone DE; Söderberg S; Olsson T; Walker BR
J Clin Endocrinol Metab; 2003 Aug; 88(8):3983-8. PubMed ID: 12915696
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.
Wake DJ; Walker BR
Endocrine; 2006 Feb; 29(1):101-8. PubMed ID: 16622297
[TBL] [Abstract][Full Text] [Related]
30. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women.
Goedecke JH; Wake DJ; Levitt NS; Lambert EV; Collins MR; Morton NM; Andrew R; Seckl JR; Walker BR
Clin Endocrinol (Oxf); 2006 Jul; 65(1):81-7. PubMed ID: 16817824
[TBL] [Abstract][Full Text] [Related]
31. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
32. Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?
Harno E; White A
Trends Endocrinol Metab; 2010 Oct; 21(10):619-27. PubMed ID: 20594868
[TBL] [Abstract][Full Text] [Related]
33. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.
Andrew R; Westerbacka J; Wahren J; Yki-Järvinen H; Walker BR
Diabetes; 2005 May; 54(5):1364-70. PubMed ID: 15855321
[TBL] [Abstract][Full Text] [Related]
34. An in vivo microdialysis coupled with liquid chromatography/tandem mass spectrometry study of cortisol metabolism in monkey adipose tissue.
Sun L; Stenken JA; Brunner JE; Michel KB; Adelsberger JK; Yang AY; Zhao JJ; Musson DG
Anal Biochem; 2008 Oct; 381(2):214-23. PubMed ID: 18638442
[TBL] [Abstract][Full Text] [Related]
35. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?
van Raalte DH; Ouwens DM; Diamant M
Eur J Clin Invest; 2009 Feb; 39(2):81-93. PubMed ID: 19200161
[TBL] [Abstract][Full Text] [Related]
36. Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes.
Bader T; Zoumakis E; Friedberg M; Hiroi N; Chrousos GP; Hochberg Z
Horm Metab Res; 2002; 34(11-12):752-7. PubMed ID: 12660894
[TBL] [Abstract][Full Text] [Related]
37. Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension.
Sukhija R; Kakar P; Mehta V; Mehta JL
Am J Cardiol; 2006 Aug; 98(4):544-8. PubMed ID: 16893715
[TBL] [Abstract][Full Text] [Related]
38. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women.
Duclos M; Marquez Pereira P; Barat P; Gatta B; Roger P
Obes Res; 2005 Jul; 13(7):1157-66. PubMed ID: 16076984
[TBL] [Abstract][Full Text] [Related]
39. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
40. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization.
Paulsen SK; Pedersen SB; Fisker S; Richelsen B
Obesity (Silver Spring); 2007 Aug; 15(8):1954-60. PubMed ID: 17712112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
